Advancing RNA medicines through safer and more effective lipid nanoparticle delivery
‘Axelyf Closes Seed Financing to Advance Next-Generation RNA-LNP Therapeutics’
August 19, 2025 - Axelyf Inc. announced the closing of $2.6 million in seed funding, led by Brunnur Ventures with participation from Omega ehf and Silfurberg ehf, with the round expected to reach $4.1 million this fall. The funds will advance Axelyf’s proprietary AXL lipid technology, which has shown superior in vivo gene editing potency, reduced toxicity, and broad potential across gene therapy models.
A team of experts, driven by passion and precision
Founded in Hafnarfjörður, Iceland, the Axelyf team leverages decades of expertise in pharmaceutical R&D and its global network of partners and collaborators to specialize in optimizing delivery systems for promising small molecule drugs derived from natural sources.